News|Events|October 9, 2026

FAQ: How Much Do You Know About ASOs?

Antisense oligonucleotides are reshaping drug design, from RNase H gapmers to inhaled delivery; this FAQ explains how they work and why trials still fail.

Antisense oligonucleotides (ASOs) are short, synthetic strands of DNA or RNA, typically 13 to 30 nucleotides long, designed to bind a complementary sequence on a target messenger RNA (mRNA) or pre-mRNA.1 Depending on its chemistry, an ASO works through 1 of 3 mechanisms. It can recruit the enzyme RNase H1 to cleave and degrade the bound transcript, it can block a splice donor or acceptor site so the spliceosome skips a mutated exon and restores a functional reading frame, or it can sterically block ribosome binding to prevent translation without triggering RNase H activity at all.1 Gene silencing calls for an RNase H-recruiting gapmer, restoring a disrupted protein calls for a splice-modulating chemistry such as a phosphorodiamidate morpholino oligomer (PMO) instead.1

Related to this article